Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Tickers ONTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.